Christian Dehlendorff1, Pär Sparén2, Birgitte Baldur-Felskov3, Eva Herweijer2, Lisen Arnheim-Dahlström2, Alexander Ploner2, Ingrid Uhnoo4, Susanne K Kjaer5. 1. Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen, Denmark. Electronic address: chrdehl@cancer.dk. 2. Dept. of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. 3. Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark. 4. Dept. of Monitoring and Evaluation, Public Health Agency of Sweden, Stockholm, Sweden. 5. Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Gynecology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Abstract
BACKGROUND: Based on immunogenicity studies, a 2 dose HPV vaccination-schedule was recently recommended for girls younger than 15 years. We aimed to investigate the effectiveness of quadrivalent HPV (qHPV) vaccination against CIN2 or worse (CIN2+), by age at vaccination, number of doses, and to test whether optimal timing of 2 doses of qHPV vaccine can confer the same level of protection as the originally recommended three dose-schedule. METHODS: A population-based cohort of all women aged 13-30 years, living in Denmark or Sweden during 2006-2013, was followed for qHPV vaccination status and first occurrence of CIN2+. RESULTS: The study cohort comprised 2,253,561 women, of which 33% were vaccinated during follow-up, and 1.7% were diagnosed with CIN2+. Vaccination at ages 13-16 and 17-19 was associated with a reduced risk of CIN2+ after 3 doses (IRR = 0.23, 95% CI 0.11-0.49, and IRR = 0.65, 95% CI 0.41-1.03, respectively), compared to being unvaccinated. After 1 and 2 doses there was a reduced risk, but not statistically significant. Women vaccinated ages 13-16 with 2 doses, where time between first and second dose was 5 months or longer showed no difference in risk compared to 3 doses. CONCLUSIONS: Women vaccinated with 3 doses of qHPV showed a reduced risk of CIN2+ if they were vaccinated before age 20, with a further reduced risk if vaccinated before age 17. Vaccination with 2 doses, with the second dose 5 months or longer after the first dose, did not yield an increased risk of CIN2+, compared to 3 doses.
BACKGROUND: Based on immunogenicity studies, a 2 dose HPV vaccination-schedule was recently recommended for girls younger than 15 years. We aimed to investigate the effectiveness of quadrivalent HPV (qHPV) vaccination against CIN2 or worse (CIN2+), by age at vaccination, number of doses, and to test whether optimal timing of 2 doses of qHPV vaccine can confer the same level of protection as the originally recommended three dose-schedule. METHODS: A population-based cohort of all women aged 13-30 years, living in Denmark or Sweden during 2006-2013, was followed for qHPV vaccination status and first occurrence of CIN2+. RESULTS: The study cohort comprised 2,253,561 women, of which 33% were vaccinated during follow-up, and 1.7% were diagnosed with CIN2+. Vaccination at ages 13-16 and 17-19 was associated with a reduced risk of CIN2+ after 3 doses (IRR = 0.23, 95% CI 0.11-0.49, and IRR = 0.65, 95% CI 0.41-1.03, respectively), compared to being unvaccinated. After 1 and 2 doses there was a reduced risk, but not statistically significant. Women vaccinated ages 13-16 with 2 doses, where time between first and second dose was 5 months or longer showed no difference in risk compared to 3 doses. CONCLUSIONS:Women vaccinated with 3 doses of qHPV showed a reduced risk of CIN2+ if they were vaccinated before age 20, with a further reduced risk if vaccinated before age 17. Vaccination with 2 doses, with the second dose 5 months or longer after the first dose, did not yield an increased risk of CIN2+, compared to 3 doses.
Authors: Anne F Rositch; Eshan U Patel; Molly R Petersen; Thomas C Quinn; Patti E Gravitt; Aaron A R Tobian Journal: Clin Infect Dis Date: 2021-05-04 Impact factor: 9.079
Authors: Michelle L Johnson Jones; Julia Warner Gargano; Melissa Powell; Ina U Park; Linda M Niccolai; Nancy M Bennett; Marie R Griffin; Troy Querec; Elizabeth R Unger; Lauri E Markowitz Journal: Am J Epidemiol Date: 2020-04-02 Impact factor: 4.897
Authors: Andreas Ährlund-Richter; Liqin Cheng; Yue O O Hu; Mikaela Svensson; Alexandra A L Pennhag; Ramona G Ursu; Linnea Haeggblom; Nathalie Grün; Torbjörn Ramqvist; Lars Engstrand; Tina Dalianis; Juan Du Journal: Front Cell Infect Microbiol Date: 2019-03-20 Impact factor: 5.293
Authors: Julia Ml Brotherton; Alison Budd; Christopher Rompotis; Natasha Bartlett; Michael J Malloy; Rachael L Andersen; Kim Ar Coulter; Peter W Couvee; Nerida Steel; Gail H Ward; Marion Saville Journal: Papillomavirus Res Date: 2019-07-15
Authors: Proma Paul; Anne Hammer; Anne F Rositch; Anne E Burke; Raphael P Viscidi; Michelle I Silver; Nicole Campos; Ada O Youk; Patti E Gravitt Journal: J Infect Dis Date: 2021-04-23 Impact factor: 5.226